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switch (OR1.6; 1.2-2.1) and discontinuation (OR1.8; 1.5-2.1). Heart failure was associ-
ated with augmentation (OR1.6; 1.0-2.5) and discontinuation (OR1.7; 1.2-2.4). Age was
inversely associated with augmentation and discontinuation and time since diabetes di-
agnosis was also inversely associated with augmentation. CONCLUSIONS: HbA1c is a
clear driver of treatment regimen changes although there are other factors also
independently related to change such as age, heart failure and baseline OAD.
PDB79
TREATMENT PATTERNS OF ORAL ANTI-DIABETIC DRUGS IN THE UK
Maguire A1, Mitchell B2
1United BioSource Corporation, London, UK, 2Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: In the UK, Oral Anti-Diabetic drugs “OAD” are administered to control
hyperglycaemia in type 2 diabetes when HbA1c exceeds 48mmol/mol. Treatment
guidelines determine initial OAD and subsequent changes in regimen depend on
HbA1c response. Hence, the aim of this study is to quantify OAD treatment
patterns. METHODS: All patients who initiated an OAD (except rosiglitazone) with
first use as index date, in the GPRD database between 1/1/2006 and 25/2/2011 were
included. Periods of continuous and overlapping prescribing (Rx) were used to
define discontinuation, switching and augmentation; a gap of 60 days since expiry
of Rx defined discontinuation. RESULTS: Of 63060 patients commencing OAD, 88%
started on metformin and 8% on gliclazide both as monotherapy. Hence, all other
OAD regimens comprised only 4% of all patients. Compared to metformin, the
gliclazide patient group was older (mean age 67 vs. 61 years) and had higher me-
dian baseline HbA1c (70 (IQR 60-95) vs. 64 (IQR 56-74) mmol/mol). The rate of dis-
continuation of baseline OAD at one year was 32% whilst the discontinuation of all
OAD was 26%. It was rare for discontinuation of OAD to be permanent; only 3.3% of
patients who discontinued in the 1st 12 months did not restart during 4 years. The
rate of switching was 6.4% and the rate of augmentation was 15% over the first year.
These rates differed according to baseline OAD. Compared to metformin the dis-
continuation rate of gliclazide was higher (41% vs. 30%), as was switching (8.4% vs.
6.1%) and augmentation (23% vs. 14%). Lastly, insulin uptake was just 2% by one
year since OAD initiation; again this was higher in the gliclazide group compared to
metformin (7% vs. 1.4%). CONCLUSIONS: Most patients initiated on metformin,
whilst for those initiating on gliclazide, discontinuation, switching, augmentation
and insulin initiation were all higher. Most patients who discontinued OAD subse-
quently restarted.
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OBJECTIVES: A myriad of pharmacologic agents are developed in attempts to con-
trol obesity, including the extension of the antiepileptic topiramate as an antiobe-
sity agent. However, concerns about the safety of such agents are mounting. This
study aimed at evaluating the cardiovascular and congenital (CC) safety of mar-
keted antiobesity agents, including topiramate. METHODS: A pharmacovigilance
analysis of adverse event reports spontaneously submitted to the US Food and
Drug Administration’s Adverse Event Reporting System (AERS) from 2004 to 2011
was conducted. The Proportional Reporting Ratio (PRR) data mining algorithm is
used to detect signals of CC adverse events that are reported for orlistat, phenter-
mine, sibutramine, and topiramate. Safety signals are detected for PRR values 2.
The values are compared within antiobesity class and to all drugs in AERS.
RESULTS: A total of 41,930 adverse event reports for antiobesity agents were sub-
mitted to the AERS during the study period. About 4% and 1% of the reports were for
cardiovascular and congenital problems, respectively. Compared to all drugs in
AERS, antiobesity agents didn’t show higher than expected reporting of cardiovas-
cular events (PRR 0.71, 95%CI 0.68-0.74). However, they showed significant safety
signals regarding congenital anomalies (PRR 7.45, 95%CI 6.82-8.0), which were
mostly attributed by topiramate. Compared to other antiobesity agents, sibut-
ramine was associated with higher cardiovascular reporting rates (PRR 4.42, 95%CI
4.0-4.85), e.g. cardiac arrhythmias, pulmonary hypertension, hypertension, coro-
nary artery disease, and stroke. Phentermine was associated with valvular heart
disease (VHD), pulmonary hypertension, and stroke. Topiramate was associated
with congenital anomalies and VHD. CONCLUSIONS: Antiobesity agents should be
prescribed with caution to patients with cardiovascular risk factors. Regulatory
authorities should define cardiovascular safety surveillance requirements for an-
tiobesity agents at postmarketing stages of product’s lifecycle. An alternative to
topiramate should be prescribed to females of childbearing age. Epidemiological
studies are warranted to test the generated hypotheses.
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OBJECTIVES: COLLECT scale was developed to assess the level of comorbidity with
an impact on treatment decision for patients with Chronic Lymphocytic Leukae-
mia (CLL) in 5 steps: 1.-Literature review, 2.-Focus Group, 3.-Pilot study to evaluate
scale feasibility, 4.-Scale design, 5.-Scale validation in an observational, prospec-
tive phase IV study (evaluating safety profile of Rituximab in CLL). This communi-
cation presents the preliminary validation of the COLLECT scale.METHODS:A total
of 219 patients were included. The scale is to be fulfilled before initiating CLL
treatment and it collates and rates the presence of 11 relevant comorbidities. The
range of the score goes from 0 to 57 points. Four scoring clusters were predefined:
0-3 points (low comorbidity), 4-6 (mild comorbidity), 7-10 (moderate comorbidity)
and10 (high comorbidity). RESULTS: Data from 218 patients of 47 hospitals were
analyzed. Most frequent therapeutic scheme was Rituximab-Fludarabine-Cyclo-
phosphamide (R-FC) (41.3%), followed by Rituximab-Bendamustine (R-B) (29.6%)
and Rituximab-Chlorambucil (R-Cl) or schemes including alkylating agents (21.1%).
COLLECT median score (SD) was 4 (0-21) with a mean of 4.8 (3.1) points. 39.2% of
patients scored between 4-6 and 33% between 0-3. Statistically significant differ-
ences were observed in COLLECT score according to age (p0.01) and EGOG
(p0.01): the greater the age and ECOG, the greater the score. The election of in-
munochemotherapy treatment differed depending on the score cluster (p0.002):
50.6% and 32,9% of patients treated with R-FC had low and mild comorbidity level
respectively. 40,0% of patients receiving R-B had medium and 26.5% high comor-
bidity level. 50% of patients treated with R-Cl scored between 4-6 and the 23.5%
between 7-10. CONCLUSIONS: COLLECT scale allows defining 4 levels of comor-
bidities, with a very good correlation to age and ECOG status. Although the aim of
the scale is not to drive treatment decision, the study shows a trend to associate
comorbidity score with intensity of treatment.
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OBJECTIVES: Review the development and properties of systemic lupus erythem-
atosus (SLE) disease activity indices (DAIs) used in clinical trials, observational
studies, and case studies. METHODS: A structured search was conducted to iden-
tify published articles in 2005-2011 through key literature databases (EMBASE and
MEDLINE/PUBMED). Conference abstracts from targeted rheumatology, outcomes
research and quality-of-life scientific meetings in 2009-2011 were included. SLE
therapy clinical trials within the past five years were identified through the Clini-
calTrials.gov database. RESULTS: The search resulted in more than 15 different
DAIs, with the most frequently used being the British Isles Lupus Assessment
Group Scale (BILAG), European Consensus Lupus Activity Measure (ECLAM), Sys-
temic Lupus Activity Measure (SLAM), SLAM-revised (SLAM-R), Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI), SLEDAI-2K, Safety of Estrogen in
Lupus Erythematosus National-SLEDAI (SELENA-SLEDAI), and SLEDAI-2K-50 (SRI-
50). The number of items (24-97), time to complete (5-20 mins; 20 mins for some
tools in case of less physician training/familiarity), scoring (no global score or
0-105), organ/systems assessed (8-24), and subscales observed in these measures
varied widely. These eight DAIs all demonstrated substantial inter-rater reliability
(ICC.61-1.0) and had moderate to strong correlations with each other (r0.43-
0.97). Measures in all but BILAG were weighted. All of these tools require periodic
laboratory assessments such as hemoglobin, white cell count, complement levels,
or increased DNA binding. Ability to discriminate between-patient and between-
visit differences varied across the tools. CONCLUSIONS: BILAG and SELENA-SLE-
DAI or instruments derived from these tools are used widely in SLE clinical re-
search. However, given the complexity, clinician time required for accurate
completion, and need for lab assessments to complete these tools, further inves-
tigation is needed to assess their feasibility for use outside of the research arena in
routine clinical practice for optimal SLE management.
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OBJECTIVES: Lenalidomide (LEN) and bortezomib (BORT) are both effective for the
treatment of relapsed/refractory MM. The former is administered 25 mg/day orally
on days 1-21 of repeated 28-day cycles. The latter as a 1.3 mg/m2 intravenous dose
on days 1, 4, 8 and 11 for eight, three week cycles. Currently, there are no data from
head to head randomized trials comparing LEN and BORT. In the absence of such
data, an indirect comparison between LEN and BORT was performed in the re-
lapsed/refractory MM setting. Such an analysis was feasible because comparable
controls were used in the pivotal randomized trials and patients had similar base-
line characteristics. METHODS: Three pivotal randomized trials with LEN (n2)
and BORT (n1) in the relapsed/refractory setting were identified. Patients within
each trial had similar disease characteristics. Data in terms of response rate (RR),
time to progression (TTP) and overall survival (OS) were extracted from the pivotal
trials. An indirect statistical comparison between LEN and BORT was then per-
formed on these endpoints using the method of Bucher et al. (1997), which partly
maintains the benefits of randomization on the magnitude of benefit. RESULTS:
The analysis identified significant differences in efficacy between these drugs. Pa-
tients treated with LEN were significantly more likely to achieve a disease response
(OR1.92; 95%CI: 1.15 - 3.20) and to have a prolongation in TTP (HR  0.64; 95%CI:
0.44 - 0.91). The analysis also identified a trend for an OS benefit in patients receiv-
ing treatment with LEN over BORT (HR  0.71; 95%CI: 0.46 - 1.11). CONCLUSIONS:
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